All In Biotech

Drug Trial Radar · NCT05974410

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
AVM Biotechnology IncIndustry
Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Conditions

  • Glioblastoma
  • Squamous Cell Carcinoma
  • Hodgkin Lymphoma
  • Non-hodgkin Lymphoma
  • Breast Cancer
  • Prostate Cancer
  • Gastric Cancer
  • Ovarian Cancer
  • Acute Leukemia
  • Pancreatic Cancer
  • Spindle Cell Sarcoma
  • Cancer
  • Tumor, Solid
  • Tumor, Brain
  • Esophageal Andeocarcinoma
  • Mixed Phenotype AML
  • Desmoplastic Round Cell Sarcoma

Interventions

  • AVM0703Drug

    small molecule immunomodulatory drug

  • HydrocortisoneDrug

    physiologic circadian glucocorticoid

  • Proton pump inhibitorDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.